Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angus G Dalgleish

Showing results (51-60 of 83) with videos related to

Pageof 9
Sort By:
Human Vaccines & Immunotherapeutics|July 19, 2013
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanomaFerdinando C M Cananzi, Satvinder Mudan, Mary Dunne, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2011
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapyDaniel W Fowler, John Copier, Natalie Wilson, et al.
Oncology Letters|October 23, 2020
The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agentsAndrew M Gravett, Jayne L Dennis, Angus G Dalgleish, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2019
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapyAngus G Dalgleish, Silvana Di Palma, Kannon Nathan, et al.
Immunology|February 5, 2013
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomideJake Y Henry, Marie-Christine Labarthe, Brendan Meyer, et al.
Oncotarget|May 8, 2018
Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancerGustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, et al.
Molecular Biology Reports|July 15, 2009
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitroWai M Liu, Holger Laux, Jake Y Henry, et al.
Scientific Reports|January 19, 2020
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancerGustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, et al.
Oncology Reports|October 30, 2020
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancerTanzeel Khan, Alan M Seddon, Angus G Dalgleish, et al.
Oncology Reports|February 18, 2022
Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy <i>in vitro</i> and <i>in vivo</i>Wai M Liu, Nadine K Hall, Harry S Y Liu, et al.
Pageof 9

Showing results (51-60 of 83) with videos related to

Sort By:
Pageof 9
Human Vaccines & Immunotherapeutics|July 19, 2013
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanomaFerdinando C M Cananzi, Satvinder Mudan, Mary Dunne, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2011
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapyDaniel W Fowler, John Copier, Natalie Wilson, et al.
Oncology Letters|October 23, 2020
The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agentsAndrew M Gravett, Jayne L Dennis, Angus G Dalgleish, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2019
The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapyAngus G Dalgleish, Silvana Di Palma, Kannon Nathan, et al.
Immunology|February 5, 2013
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomideJake Y Henry, Marie-Christine Labarthe, Brendan Meyer, et al.
Oncotarget|May 8, 2018
Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancerGustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, et al.
Molecular Biology Reports|July 15, 2009
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitroWai M Liu, Holger Laux, Jake Y Henry, et al.
Scientific Reports|January 19, 2020
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancerGustavo A Arias-Pinilla, Angus G Dalgleish, Satvinder Mudan, et al.
Oncology Reports|October 30, 2020
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancerTanzeel Khan, Alan M Seddon, Angus G Dalgleish, et al.
Oncology Reports|February 18, 2022
Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy <i>in vitro</i> and <i>in vivo</i>Wai M Liu, Nadine K Hall, Harry S Y Liu, et al.
Pageof 9